Unicycive Therapeutics, Inc.
NASDAQ:UNCY
0.4347 (USD) • At close October 21, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|
| Revenue
| 0.675 | 0.951 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 0.284 | 0.007 | 0.001 | 0 | 0 | 0 |
| Gross Profit
| 0.391 | 0.944 | -0.001 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.579 | 0.993 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 12.902 | 12.436 | 6.08 | 1.015 | 0.795 | 0.344 |
| General & Administrative Expenses
| 8.547 | 6.567 | 2.897 | 1.005 | 1.168 | 0.608 |
| Selling & Marketing Expenses
| -0.284 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 8.263 | 6.567 | 2.897 | 1.005 | 1.168 | 0.608 |
| Other Expenses
| 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Expenses
| 21.165 | 19.003 | 8.977 | 2.02 | 1.963 | 0.952 |
| Operating Income
| -20.774 | -18.052 | -8.977 | -2.02 | -1.963 | -0.952 |
| Operating Income Ratio
| -30.776 | -18.982 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -9.77 | -0.006 | -1.04 | -0.244 | -0.202 | -0.168 |
| Income Before Tax
| -30.544 | -18.058 | -10.017 | -2.264 | -2.165 | -1.12 |
| Income Before Tax Ratio
| -45.25 | -18.988 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.116 | 0.006 | 0.615 | 0.244 | 0.139 | -0.952 |
| Net Income
| -30.544 | -18.064 | -10.632 | -2.508 | -2.304 | -1.12 |
| Net Income Ratio
| -45.25 | -18.995 | 0 | 0 | 0 | 0 |
| EPS
| -1.24 | -1.2 | -0.71 | -0.16 | -0.15 | -0.074 |
| EPS Diluted
| -1.24 | -1.2 | -0.71 | -0.16 | -0.15 | -0.074 |
| EBITDA
| -20.49 | -18.052 | -8.977 | -2.02 | -1.963 | -0.952 |
| EBITDA Ratio
| -30.356 | -18.982 | 0 | 0 | 0 | 0 |